Efficacy News and Research

RSS
DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Researchers find minocycline antibiotics effective for fragile X syndrome

Researchers find minocycline antibiotics effective for fragile X syndrome

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NIH awards second $8 million grant for research into health effects of botanical estrogens

NIH awards second $8 million grant for research into health effects of botanical estrogens

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

Personalized reminders effective in encouraging seniors to get annual flu shots

Personalized reminders effective in encouraging seniors to get annual flu shots

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.